옵션 체인은 다양한 행사가격과 만기일에 대한 Galmed Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Galmed Pharmaceuticals에 대한 시장 심리를 평가합니다..

Galmed Pharmaceuticals (NASDAQ:GLMD) 주식, 옵션 체인

Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Exclusives

Trading Ideas

AAPL

AMZN

DRUG

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 10월에 벤징가 프로에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 실적은 11월 1일 기준이며 배당금은 포함되지 않았다.

독점: 벤징가 프로에서 10월 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, DJT 순위는?

Nvidia,Logo,On,Mobile,Phone,Screen,Company,Shares,Rise,Or

APLD

CNEY

GOVX

IMRX

LUMN

NDRA

SMMT

TNON

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

Stock_Whisper_Index_Logo_6-copy

GOLD

매주 ‘벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)&#39;는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 끌고 있는 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 투자자들이 몰래 주시하지만 아직 말하지 않는 주식 5종목

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals Ltd

<ul>
<li>Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways.</li>
<li>Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets.</li>
<li>Strategic collaboration with Proteas Health positions Galmed at the forefront of AI-driven biomarker-guided therapeutics.</li>
</ul>
TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver, cardiometabolic diseases and GI oncological indications, today announced a major scientific and strategic milestone: the discovery of a proprietary pharmacodynamic (PD) blood-based biomarker signature for its lead candidate, Aramchol — the industry's most clinically advanced stearoyl-CoA desaturase 1 (SCD1) inhibitor.

News

Galmed Pharma Announces Discovery Of Proprietary PD Blood-Based Biomarker Signature For Aramchol, Clinically Advanced Stearoyl-Coa Desaturase 1 Inhibitor

Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.89) by 30.34 percent. This is a 70.48 percent increase over losses of $(2.10) per share from the same period last year.

Earnings

Earnings Beats

Galmed Pharmaceuticals Q1 EPS $(0.62) Beats $(0.89) Estimate

WIIM

Galmed Pharmaceuticals shares are trading higher after the company announced results from its first set of oncology studies.

<ul>
<li>Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor growth in mice models.</li>
<li>The cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling.</li>
<li>A Phase 1b Study of the addition of Aramchol to Regorafenib in patients with advanced GI cancers is planned to be initiated at VCU's Massey Cancer Center in Q4 2025.</li>
<li>Leveraging on its long-standing experience in liver and metabolic diseases, Galmed plans to advance the novel combination oncology program in parallel to the recently announced Semaglutide GLP-1 development.</li>
</ul>
TEL AVIV, Israel, May 6, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has shown that Aramchol enhances the liver / colorectal cancer-approved therapeutic Regorafenib effects in liver and colon cancers in-vitro and in-vivo models.

Galmed Pharma: First Set Of Oncology Studies Show Aramchol Enhances Liver / Colorectal Cancer-approved Therapeutic Regorafenib Effects In Liver And Colon Cancers In-vitro And In-vivo Models

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday.
The Dow traded down 0.27% to 40,004.11 while the NASDAQ fell 1.19% to 17,175.43. The S&amp;P 500 also fell, dropping, 0.72% to 5,485.36.
Check This Out: <a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a>
Leading and Lagging Sectors Financial shares jumped by 0.6% on Monday.
In trading on Monday, information technology fell by 0.6%.
Top Headline
Roper Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) reported better-than-expected earnings for its first quarter and raised its forecast.
The company posted first-quarter adjusted earnings per share of $4.78, beating the street view of $4.74. Quarterly sales of $1.88 billion outpaced the analyst consensus estimate of $1.82 billion.
Roper Technologies expects fiscal 2025 adjusted earnings per share of $19.80-$20.05 (compared to a previous outlook of $19.75-$20.00), versus the $19.92 estimate. It increased its full-year total revenue growth outlook to ~12% or $7.88 billion (compared to a previous outlook of 10%+ or $7.74 billion) and an analyst estimate of $7.74 billion. It reiterated organic revenue growth of +6-7%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares shot up 46% to $2.2999. Galmed signed a term sheet for the development of novel semaglutide sublingual formulation.</li>
<li>Shares of CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>)got a boost, surging 31% to $29.21 after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares were also up, gaining 42% to $1.15 after the company signed a secured credit facility with Yorkville Advisors. The company also reported preliminary first-quarter results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares dropped 28% to $0.0935 after the company announced it approved a plan to implement a workforce reduction.</li>
<li>Shares of Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) were down 15% to $16.86.</li>
<li>Protara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) was down, falling 19% to $3.4899 as the company announced interim results highlighting durable clinical responses with TARA-002 In high-risk NMIBC.</li>
</ul>
Commodities In commodity news, oil traded down 2% to $61.78 while gold traded up 0.6% at $3,316.80.
Silver traded down 0.5% to $32.845 on Monday, while copper rose 0.1% to $4.90.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.74%, Germany's DAX 40 gained 0.67% and France's CAC 40 gained 0.87%. Spain's IBEX 35 Index gained 0.81%, while London's FTSE 100 rose 0.30%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 surging 0.38%, China's Shanghai Composite falling 0.20%, Hong Kong's Hang Seng Index falling 0.04% and India's BSE Sensex gaining 1.27%.
Economics
The Dallas Fed manufacturing index will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45037469/stride-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday">Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For</a> Monday.</li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Markets

CGON

GRPN

PLUG

SPRB

TARA

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 150 points on Monday.
Following the market opening Monday, the Dow traded up 0.47% to 40,300.68 while the NASDAQ rose 0.13% to 17,405.94. The S&amp;P 500 also rose, gaining, 0.31% to 5,542.29.
Check This Out: <a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a>
Leading and Lagging Sectors Industrials shares jumped by 0.7% on Monday.
In trading on Monday, information technology fell by 0.4%.
Top Headline
Domino&#8217;s Pizza, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) reported better-than-expected earnings for its first quarter on Monday.
The company posted quarterly earnings of $4.33 per share which beat the analyst consensus estimate of $4.07 per share. The company reported quarterly sales of $1.11 billion which missed the analyst consensus estimate of $1.13 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares shot up 47% to $2.32. Galmed signed a term sheet for the development of novel semaglutide sublingual formulation.</li>
<li>Shares of CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>)got a boost, surging 36% to $30.47 after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.</li>
<li>NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) shares were also up, gaining 53% to $2.75. NaaS Technology, last week, announced a 1-for-800 ADS ratio change.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares dropped 31% to $0.09 after the company announced it approved a plan to implement a workforce reduction.</li>
<li>Shares of Pineapple Financial Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NASDAQ">PAPL</a>) were down 17% to $0.2241.</li>
<li>Protara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) was down, falling 24% to $3.30 as the company announced interim results highlighting durable clinical responses with TARA-002 In high-risk NMIBC.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $62.92 while gold traded up 0.3% at $3,306.70.
Silver traded down 0.3% to $32.91 on Monday, while copper rose 0.4% to $4.9120.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.7%, Germany's DAX 40 gained 0.7% and France's CAC 40 gained 1%. Spain's IBEX 35 Index gained 0.7%, while London's FTSE 100 rose 0.4%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 surging 0.38%, China's Shanghai Composite falling 0.20%, Hong Kong's Hang Seng Index falling 0.04% and India's BSE Sensex gaining 1.27%.
Economics
The Dallas Fed manufacturing index will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45037469/stride-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday">Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For</a> Monday. </li>
</ul>
Photo via Shutterstock

NAAS

PAPL

Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings

<ul>
<li>Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. &nbsp;</li>
<li>Aramchol, a first-in-class SCD1 inhibitor, will be studied in combination with standard therapies for advanced colorectal and liver cancers, aiming to reverse treatment resistance and improve outcomes in these high-mortality cancers. &nbsp;</li>
<li>Collaboration builds on breakthrough findings published in Nature Communications <a href="https://doi.org/10.1038/s41467-023-41852-z">(https://doi.org/10.1038/s41467-023-41852-z</a>) linking lipid metabolism to cancer drug resistance, supporting Aramchol's novel mechanism as a promising, synergistic approach.</li>
<li>This initiative is part of a strategic expansion of Galmed's pipeline beyond liver disease into oncology, targeting a large market potential with significant unmet need and reinforcing Galmed's focus on cost-effective, innovative therapies.</li>
</ul>

Biotech

Contracts

General

Galmed Pharmaceuticals  Enters Sponsored Project Agreement With Virginia Commonwealth University To Evaluate Aramchol's Effect On Overcoming Drug Resistance In Gastrointestinal Cancers

<ul>
<li>Analysis of blood samples from patients treated with&nbsp;Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and physiological effects of the drug.</li>
<li>The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in markers of chronic systemic inflammation, oxidative and cardiac stress, and atherosclerotic plaque pathogenesis.
<ul>
<li>Data also show a significant decrease in ANP (Atrial Natriuretic Peptide), a clinically validated marker for heart failure. &nbsp;</li>
</ul>
</li>
</ul>

Galmed Unveils Pharmacodynamic Blood Markers For Aramchol

– AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development &nbsp;– Aramchol Meglumine, a New Chemical Entity (NCE) protected by patents until 2035, is being developed both as a standalone agent and in novel drug combinations for multiple indications influenced by fatty acid metabolism &nbsp;– Initial findings suggest that the new Aramchol Meglumine formulation offers higher bioavailability than Aramchol free acid and that a once-daily, oral 200 mg dose is likely to be optimal for future trials, supporting improved patient compliance and potentially lowering manufacturing costs
TEL AVIV, Israel, April 10, 2025 /PRNewswire/ --&nbsp;Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine.
Galmed has successfully advanced Aramchol acid through six clinical trials (up to Ph3) enrolling 661 subjects, establishing both its overall safety and its efficacy in treating NASH (MASH). The N-methylglucamine (meglumine) salt of Aramchol exhibits notable advantages over Aramchol acid, including enhanced solubility, absorption, and systemic exposure, translating to higher bioavailability. In recognition of these benefits, Aramchol Meglumine received NCE patent protection extending until 2035.
Previously, the FDA approved the transition from Aramchol acid to Aramchol Meglumine under a new IND, leveraging cross-reference to the substantial preclinical and clinical data amassed in recent years for Aramchol. The only requirement for this transition was a bioavailability study to compare the two formulations.
The AM-001 study was conducted in response to that FDA request and is also designed to help identify the doses best suited for advancing Aramchol Meglumine into Phase 2 studies. It consists of two parts, comparing single doses of Aramchol acid and Aramchol Meglumine in healthy volunteers. Part 2 of the study is anticipated to conclude in the second half of 2025.
In Part 1 of AM-001, preliminary results demonstrate that a 400 mg dose of Aramchol Meglumine suspension achieved an area under the curve (AUC) nearly double that of Aramchol acid tablets. Based on these outcomes, 200 mg once daily appears to be the optimal dose for subsequent clinical trials. This once-daily regimen not only simplifies patient adherence (moving from twice-daily to once-daily) but is also expected to reduce the overall cost of goods.
"Aramchol is the most advanced down regulator of SCD-1 (Stearoyl – CoA desaturase) in clinical development. Inhibition of SCD-1 has been recently investigated in multiple indications, re-emphasizing its metabolic master switch potential and importance in multiple organs and functions. We expect that the long patent runway of Aramchol Meglumine will allow us to develop the full therapeutical potential of the drug in the planned expansion in cardiometabolic diseases and gastrointestinal cancers we recently announced," said Allen Baharaff, President and CEO of Galmed Pharmaceuticals.

Galmed Announces Part 1 Results From AM-001 Study Of Aramchol Meglumine, An Enhanced Formulation Of The Most Clinically Advanced SCD1 Inhibitor

Maxim Group analyst Naz Rahman downgrades Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) from Buy to Hold.

Downgrades

Analyst Ratings

Maxim Group Downgrades Galmed Pharmaceuticals to Hold

TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the 'SEC').
 &nbsp;

Galmed Pharmaceuticals Files Annual Report On Form 20-F For Fiscal Year Ended December 31, 2024

Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Resmetirom (MGL-3196, Rezdiffra) for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis.

Global

Galmed Pharmaceuticals Announces The Grant Of A New Patent Related To Aramchol; Patent Covers The Use Of A Combination Therapy Of Aramchol And Resmetirom For The Treatment Of Non-Alcoholic Steatohepatitis, Also Known As Metabolic Dysfunction-Associated Steatohepatitis, And Liver Fibrosis

Galmed Pharmaceuticals Shares Resumed Trade

Galmed Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 67.9%

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12239712?requestToken=eyJzdWIiOiI3OTM4NzBkYy02ZTJiLTRlNzQtOWFmMC01ZjViMmQyYjMyYTkiLCJ2ZXIiOiIzNTEwMDc4OS0wM2FkLTQ2MDAtOThkOS0wZGI4NDdjMzBjYzAiLCJleHAiOjB9" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12239712?requestToken=eyJzdWIiOiI3OTM4NzBkYy02ZTJiLTRlNzQtOWFmMC01ZjViMmQyYjMyYTkiLCJ2ZXIiOiIzNTEwMDc4OS0wM2FkLTQ2MDAtOThkOS0wZGI4NDdjMzBjYzAiLCJleHAiOjB9">https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12239712?requestToken=eyJzdWIiOiI3OTM4NzBkYy02ZTJiLTRlNzQtOWFmMC01ZjViMmQyYjMyYTkiLCJ2ZXIiOiIzNTEwMDc4OS0wM2FkLTQ2MDAtOThkOS0wZGI4NDdjMzBjYzAiLCJleHAiOjB9</a>

Galmed Research And Development Granted U.S. Patent #12239712 Combination therapy for the treatment of liver disease

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">and individual tickers.</a>
Here is a look at the most-searched stocks on Benzinga Pro for October 2024. Current prices and year-to-date performance are based on Nov. 1 and do not include dividends.
1. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>Current Price: $248.98</li>
<li>52-Week Range: $138.80 to $273.54</li>
<li>Year-to-Date Return: +0.2%</li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow">July</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n">August</a>/<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple">September </a>Ranking: 1st/3rd/3rd</li>
</ul>
2. NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>Current Price: $135.37</li>
<li>52-Week Range: $44.90 to $144.42</li>
<li>Year-to-Date Return: +181.0%</li>
<li>July/August/September Ranking: 2nd/1st/1st</li>
</ul>
3. Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
<ul>
<li>Current Price: $30.56</li>
<li>52-Week Range: $11.75 to $79.38</li>
<li>Year-to-Date Return: +75.7%</li>
<li>July/August/September Ranking: Not in Top 20/Not in Top 20/20th</li>
</ul>
4. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>Current Price: $571.04</li>
<li>52-Week Range: $426.56 to $586.12</li>
<li>Year-to-Date Return: +20.8%</li>
<li>July/August/September Ranking: 3rd/2nd/2nd</li>
</ul>
5. Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>Current Price: $26.05</li>
<li>52-Week Range: $24.92 to $122.90</li>
<li>Year-to-Date Return: -8.8%</li>
<li>July/August/September Ranking: 19th/4th/7th</li>
</ul>
6. Bright Minds Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>)
<ul>
<li>Current Price: $48.18</li>
<li>52-Week Range: $0.93 to $79.02</li>
<li>Year-to-Date Return: +2,518.5%</li>
<li>July/August/September Ranking: Not in Top 20 in Any</li>
</ul>
7. Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
<ul>
<li>Current Price: $141.86</li>
<li>52-Week Range: $110.22 to $227.30</li>
<li>Year-to-Date Return: +2.4%</li>
<li>July/August/September Ranking: 14th/8th/Not in Top 20</li>
</ul>
8. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>Current Price: $222.91</li>
<li>52-Week Range: $164.08 to $237.49</li>
<li>Year-to-Date Return: +20.1%</li>
<li>July/August/September Ranking: 7th/6th/4th</li>
</ul>
9. Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>)
<ul>
<li>Current Price: $2.37</li>
<li>52-Week Range: $0.26 to $21.09</li>
<li>Year-to-Date Return: -78.7%</li>
<li>July/August/September Ranking: Not in Top 20 in Any</li>
</ul>
10. Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)
<ul>
<li>Current Price: $21.67 </li>
<li>52-Week Range: $5.35 to $28.12 </li>
<li>Year-to-Date Return: +104.4% </li>
<li>July/August/September Ranking: Not in Top 20 in Any </li>
</ul>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110424">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;in October 2024.
11. Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
12. Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)
13. Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
14. Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
15. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
16. MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)
17. Genprex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>)
18. SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)
19. Boeing Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)
20. TeraWulf Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>)
Why It's Important: Tesla, regularly among the most searched tickers on the site, climbed the leaderboard to be the most-searched ticker on Benzinga Pro in October. The stock was third in the past two months, but ranked first in July. 
Nvidia ranked second in October, dropping from first place over the last two months. The technology giant briefly passed Apple and Microsoft to be the<a href="https://www.benzinga.com/markets/equities/24/10/41551461/nvidia-overtakes-apple-as-worlds-most-valuable-company-again"> most valuable company in the world.</a>
One of the biggest movers in October was Trump Media &amp; Technology Group, a media company co-founded by former President Donald Trump. The stock has surged in recent weeks ahead of Election Day. Trump's odds of winning the 2024 presidential election have <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41635149/2024-election-odds-on-polymarket-kalshi-show-trump-will-win-why-they-might-be-wrong">increased across prediction markets</a> and sports betting apps.
The stock has also been highlighted as a potential <a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-">short-squeeze stock </a>with high short interest. A 2024 election win by Trump could see the stock shoot higher. Likewise, the stock could fall significantly if Trump loses the election.
Trump Media &amp; Technology Group will likely be among the most searched tickers on Benzinga Pro in November with Election Day happening on Nov. 5. The stock was the 20th most searched ticker in September and wasn't in the top 20 in August or July, ranking just outside the top 20.
The SPDR S&amp;P 500 ETF Trust falls to fourth place from second in the past two months, likely due more to the surge in interest in the stocks mentioned above and not less interest in the S&amp;P 500 market index. Although it should be noted that the Invesco QQQ Trust ETF, which tracks the Nasdaq 100 Index, fell from sixth place to 15th in October, potentially signaling less interest in ETFs and market indexes.
Other newcomers to the top 10 were Bright Minds Biosciences, Tevogen Bio and Oklo, who have each not previously been among the top 20 most-searched tickers in any given month. Tevogen shares have fallen significantly in 2024, while Bight Minds Sciences and Oklo are each up over 100% in 2024.
Advanced Micro Devices also returned to the top 10, ranking seventh, which comes after falling out of the top 20 in September. The stock has regularly gone back and forth between the top 10 and top 20 each month in 2024.
Dropping out of the top 10 along with Invesco QQQ were Wheeler Real Estate Investment Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>), Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>), Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>). &nbsp;
Overall the month of October saw five of the same top 10 tickers from September and eight of the top 20 tickers from September.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41665149/these-10-stocks-were-s-p-500s-top-performers-in-bidens-first-year-could-the-trend-continue-if-h">These 10 Stocks Were S&amp;P 500&#8217;s Top Performers In Biden&#8217;s First Year: Could Trend Continue If Harris Wins 2024 Election?</a></li>
</ul>

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

Buybacks

Galmed Pharmaceuticals Shareholders Approve Proposal At Special Meeting; Amends Equity Purchase Agreement With Yorkville To Increase Commitment Amount From $10M To $20M

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">and individual tickers.</a>
Here is a look at the most-searched stocks on Benzinga Pro for September 2024. Current prices and year-to-date performance are based on Sept. 30 and do not include dividends.
1. NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ol></ol>
<ol></ol>
<ol></ol>
<ol></ol>
<ul>
<li>Current Price: $121.44</li>
<li>52-Week Range: $39.23 to $140.76</li>
<li>Year-to-Date Return: +152.1%</li>
<li><a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple">June</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow">July</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n">August </a>Ranking: 1st/2nd/1st</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>Current Price: $573.76</li>
<li>52-Week Range: $409.22 to $574.71</li>
<li>Year-to-Date Return: +21.4%</li>
<li>June/July/August Ranking: 3rd/3rd/2nd</li>
</ul>
3. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>Current Price: $261.63</li>
<li>52-Week Range: $138.80 to $271.00</li>
<li>Year-to-Date Return: +5.3%</li>
<li>June/July/August Ranking: 4th/1st/3rd</li>
</ul>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100224">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
4. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>Current Price: $233.00</li>
<li>52-Week Range: $164.08 to $237.23</li>
<li>Year-to-Date Return: +25.5%</li>
<li>June/July/August Ranking: 5th/7th/6th</li>
</ul>
5. Wheeler Real Estate Investment Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)
<ul>
<li>Current Price: $8.09</li>
<li>52-Week Range: $2.90 to $1,126.80</li>
<li>Year-to-Date Return: -92.8%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
6. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>Current Price: $488.07</li>
<li>52-Week Range: $342.35 to $503.52</li>
<li>Year-to-Date Return: +21.2%</li>
<li>June/July/August Ranking: 11th/11th/9th</li>
</ul>
7. Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>Current Price: $416.40</li>
<li>52-Week Range: $226.59 to $1,229.00</li>
<li>Year-to-Date Return: +45.9%</li>
<li>June/July/August Ranking: 10th/19th/4th</li>
</ul>
8. Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>)
<ul>
<li>Current Price: $6.86</li>
<li>52-Week Range: $2.73 to $23.80</li>
<li>Year-to-Date Return: +29.9%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
9. Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)
<ul>
<li>Current Price: $23.46</li>
<li>52-Week Range: $18.51 to $51.28</li>
<li>Year-to-Date Return: -50.9%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
10. Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
<ul>
<li>Current Price: $8.05</li>
<li>52-Week Range: $2.09 to $13.25</li>
<li>Year-to-Date Return: +241.1%</li>
<li>June/July/August Ranking: Not in Top 20/Not in Top 20/20th</li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;in September 2024.
11. Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)
12. Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
13. Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
14. Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>)
15. CN Energy Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>)
16. Quhuo Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>)
17. ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>):
18. Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>)
19. Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>)
20. Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
Why It&#8217;s Important:&nbsp;Nvidia was the top searched stock on Benzinga Pro for the month of September once again. The stock has ranked first or second for every month tracked since February, sometimes alternating with SPY or Tesla.
The SPDR S&amp;P 500 ETF Trust ranked second for a second straight month, which comes as the S&amp;P 500 tracking index hit new all-time highs in the month of September.
Tesla, which topped the month of July, has ranked third for two straight weeks. The stock has ranked among the top four stocks searched in each month tracked in 2024.
The bigger story in September were the newcomers and the stocks that dropped off.
Newcomers to the top 10 included Wheeler Real Estate, Galmed, Intel and Intuitive. Of the four stocks, only Intuitive had ranked in the top 20 over the last three months. The newcomers all had catalysts in the last month that made their stocks highly volatile.
On the 11th through 20th portion of the list, the stocks were all different from the previous month with Intuitive moving to the top 10 and Palantir going from 7th to 12th and the other stocks all new to the top 20.
Several of the companies ranked in the bottom part of the top 20 are penny stocks trading at less than $5 per share that saw wide moves that saw increased interest from Benzinga traders.
One of the bigger names to make the top 20, by name recognition, is Trump Media &amp; Technology Group, the company that counts former President Donald Trump as a co-founder. The stock has been highly volatile during the 2024 election cycle.
Dropping out of the top 10 were Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>), Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) and the aforementioned Palantir.
Other big names that exited the top 20 include Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) that was 13th in August and fell to 24th to narrowly miss the list.
Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), which has frequently appeared in the top 20 and was ranked 15th in August dropped out of the top 20.
Overall the month of September saw six of the same top 10 tickers from August and eight of the top 20 tickers from August.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/07/39603613/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-first-half-2024-where-do-nvidia-tesla-pala">EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In First Half 2024 – Where Do Nvidia, Tesla, Palantir, GameStop Rank?</a></li>
</ul>
Image: Shutterstock

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

Galmed Pharmaceuticals shares are trading lower. The company announced that results of its Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis has been published in Hepatology.

<ul>
<li>The paper re-iterates the significant&nbsp;anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)</li>
<li>Data is confirmed using 3 objective measurements; NASH&nbsp;CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis</li>
<li>Continuous&nbsp;histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology</li>
</ul>
TEL AVIV, Israel, Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced today that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in&nbsp;<a href="https://journals.lww.com/hep/abstract/9900/aramchol_improves_hepatic_fibrosis_in_metabolic.930.aspx">Hepatology</a>.&nbsp;

Galmed 1-Year Results Of The Open-Label Part Of Its Global Phase 3 Trial Of Aramchol In 150 Patients With NASH And Fibrosis Have Been Published In Hepatology

Small Cap

Press Releases

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Emerging Growth Leaders: – INEO, PLUG, HIT, GLMD, OMEX, More Stocks Inside – Health, Energy, Mining, and Defense Making Headlines

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

Comments

Galmed Pharmaceuticals

Galmed Pharmaceuticals (GLMD) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌